SciSparc Ltd. (SPRC)
NASDAQ: SPRC · Real-Time Price · USD
0.446
-0.020 (-4.37%)
At close: Feb 21, 2025, 4:00 PM
0.451
+0.005 (1.17%)
After-hours: Feb 21, 2025, 6:58 PM EST
SciSparc Revenue
SciSparc had revenue of $840.00K in the half year ending June 30, 2024. This brings the company's revenue in the last twelve months to $1.75M, down -47.36% year-over-year. In the year 2023, SciSparc had annual revenue of $2.88M with 113.73% growth.
Revenue (ttm)
$1.75M
Revenue Growth
-47.36%
P/S Ratio
0.33
Revenue / Employee
$582,333
Employees
3
Market Cap
1.60M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
SPRC News
- 5 days ago - SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology - GlobeNewsWire
- 18 days ago - SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico - GlobeNewsWire
- 5 weeks ago - SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement - GlobeNewsWire
- 5 weeks ago - SciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric Vehicles - GlobeNewsWire
- 6 weeks ago - SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results - GlobeNewsWire
- 6 weeks ago - Why Is Psychedelic-SciSparc Stock Trading Higher On Monday? - Benzinga
- 6 weeks ago - SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment - GlobeNewsWire
- 7 weeks ago - SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder - GlobeNewsWire